Association of Suicidality and Depression With 5α-Reductase Inhibitors
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Importance: There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective: To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement. Design, Setting, and Participants: A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 years or older (median [IQR] age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a 5α-reductase inhibitor during the study period (2003 through 2013). Participants were matched (using a propensity score that included 44 of our 96 covariates that included medical comorbidities, medication usage, and health care system utilization) to an equal number of men not prescribed a 5α-reductase inhibitor. Exposures: Duration of finasteride or dutasteride usage. Main Outcomes and Measures: Suicide. Secondary outcomes were self-harm and depression. Results: Men who used 5α-reductase inhibitors were not at a significantly increased risk of suicide (HR, 0.88; 95% CI, 0.53-1.45). Risk of self-harm was significantly increased during the initial 18 months after 5α-reductase inhibitor initiation (HR, 1.88; 95% CI, 1.34-2.64), but not thereafter. Incident depression risk was elevated during the initial 18 months after 5α-reductase inhibitor initiation (HR, 1.94; 95% CI, 1.73-2.16), and continued to be elevated, but to a lesser degree, for the remainder of the follow-up period (HR, 1.22; 95% CI, 1.08-1.37). The absolute increases in the event rates for these 2 outcomes were 17 per 100 000 patient-years and 237 per 100 000 patient-years, respectively. The type of 5α-reductase inhibitor (finasteride or dutasteride) did not significantly modify the observed associations with suicide, self-harm, and depression. Conclusions and Relevance: In a large cohort of men ages 66 years or older, we did not demonstrate an increased risk of suicide associated with 5α-reductase inhibitor use. However, the risk of self-harm and depression were increased compared with unexposed men. This is in keeping with postmarketing experience and patient concerns, and discontinuation of the medication in these circ umstances may be appropriate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749
Hawton, K., & van Heeringen, K. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60372-x · Cited by 1,671
Clinical diagnosis of depression in primary care: a meta-analysis
Mitchell, A. J., Vaze, A., & Rao, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60879-5 · Cited by 1,251
Hamza, C. A., Stewart, S. L., & Willoughby, T. (2012) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.05.003 · Cited by 769
Bioavailable Testosterone and Depressed Mood in Older Men: The Rancho Bernardo Study
Barrett-Connor, E., von Mühlen, D. G., & Kritz-Silverstein, D. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5495 · Cited by 472
Risk of incident diabetes among patients treated with statins: population based study
Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013) · BMJ · doi:10.1136/bmj.f2610 · Cited by 404
Factors associated with suicide in patients with genitourinary malignancies
Klaassen, Z., Jen, R. P., DiBianco, J. M., Reinstatler, L., Li, Q., Madi, R., Lewis, R. W., Smith, A. M., Neal, D. E., Moses, K. A., et al. (2015) · Cancer · doi:10.1002/cncr.29274 · Cited by 95
Validation of suicide and self‐harm records in the Clinical Practice Research Datalink
Thomas, K. H., Davies, N., Metcalfe, C., Windmeijer, F., Martin, R. M., & Gunnell, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12059 · Cited by 84
5α-Reductases in human physiology: an unfolding story
Traish, A. M. (2012) · Endocrine Practice · doi:10.4158/ep12108.ra · Cited by 57
Handa, R. J., Kudwa, A. E., Donner, N. C., McGivern, R. F., & Brown, R. (2013) · Brain Research · doi:10.1016/j.brainres.2013.07.021 · Cited by 56
Overend, K., Bosanquet, K., Bailey, D., Foster, D., Gascoyne, S., Lewis, H., Nutbrown, S., Woodhouse, R., Gilbody, S., & Chew-Graham, C. (2015) · BMC Family Practice · doi:10.1186/s12875-015-0362-2 · Cited by 30
National trends in hospital-treated self-harm events among middle-aged adults
Olfson, M., Wang, S., & Blanco, C. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.08.004 · Cited by 21
Cited by
Locci, A., & Pinna, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13843 · Cited by 132
Raber, J., Arzy, S., Bertolus, J. B., Depue, B., Haas, H. E., Hofmann, S. G., Kangas, M., Kensinger, E., Lowry, C. A., Marusak, H. A., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.015 · Cited by 62
Gamble, J.-M., Chibrikov, E., Midodzi, W. K., Twells, L. K., & Majumdar, S. R. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023830 · Cited by 52
Wu, Y. (., McArthur, E., Dixon, S., Dirk, J. S., & Welk, B. K. (2018) · International Journal of Obstetric Anesthesia · doi:10.1016/j.ijoa.2018.04.005 · Cited by 22
Self-citationCortez, G. L., Hassun, K., Linhares, L. R. P., Florenço, V., Pinheiro, M. V. B., & Nascimento, M. M. D. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2024.08.004 · Cited by 16
Metadata
- Authors
- Welk, B., McArthur, E., Ordon, M., Anderson, K. K., Hayward, J., & Dixon, S.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2017-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 683
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2600604755
- Cited by
- 127
- References
- 12
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.